BarentsKrans advises Horticoop on the acquisition of the shares in SmartCoat B.V.
BarentsKrans has advised Horticoop on the acquisition of the shares in SmartCoat B.V. from Finoxa. Horticoop already held 80% of the shares and became the sole shareholder of Smartcoat at the end of 2020 as a result of this transaction. SmartCoat is with her brands Redusysems and Sudlac active in more than 50 countries and
BarentsKrans advises Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics
BarentsKrans has advised Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics. Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS (Central Nervous System) disorders. “At Angelini Pharma, we are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our
BarentsKrans advises the sell side on the sale of Yellowstar
BarentsKrans has advised the sell side on the sale and transfer of the shares in Yellow Star Solution Holding B.V. to ICT Group N.V. Yellowstar, founded in 2009 and located in Barendrecht, makes supply chains fully predictable and transparent. Yellowstar also realises customized software solutions for transport management systems, dynamic planning boards, terminal operating systems,
Foreign direct investments screening in the Netherlands?
Dutch Government traditionally has been reluctant to regulate domestic and cross border take overs and investments in general and especially foreign direct investment (FDI). On the OECD FDI Restrictiveness Index of 2019, the Netherlands had the sixth position of countries with the lowest restrictiveness. But times are a changing. Fueled by shifts in geopolitical powers
Booking.com judgment: jurisdiction for actions based on an abuse of a dominant position
On 24 November 2020, the European Court of Justice (ECJ) ruled that the German hotel Wikingerhof, which used the Booking.com platform, may bring proceedings based on an abuse of a dominant position before the courts of Germany, although defendant Booking.com was domiciled in the Netherlands. The decision stems from the questions of the German referring
Legal 500: an overview of patent litigation in the Netherlands
BarentsKrans’ IP & Technology team provided an overview, in the form of an Q&A, of the most important aspects of patent procedures in The Netherlands for Legal 500. The Q&A provides for a view on the main questions about infringement and (un)validity of patents and important procedural information which is in particular relevant in an
BarentsKrans advises on the sell side of the acquisition of Sanidump
BK has advised on the sell side of the acquisition of Sanidump by the FG-group, the holding company of the Dutch franchise formulas Sanisale.com, Keukensale.com, Sanistunter and Keukenstunter. Sanidump operates 41 megastores and is the largest and fastest growing independent sanitary shop in the Netherlands and has over 24 years of experience in that field.
Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed
In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent
In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Pharma update | Cross-border preliminary injunction granted regarding deferasirox
At the request of Novartis the Provisions Judge of the District Court of The Hague granted a preliminary injunction against Mylan BV for the alleged imminent infringement of Novartis’ paediatric extension (‘PE’) of Dutch SPC 300248 (‘SPC ‘248’) based on EP 0 914 118 (‘EP ‘118’).The product at issue contains deferasirox as the active ingredient